Evidence map›Paper›PMID 41541060›Full record

ArticleBiosafety and health2025

Clinical characteristics of SARS-CoV-2 infection in patients with chronic hepatitis B during interferon antiviral therapy.

Shiyu Wang, Ziyu Zhang, Xinxin Li, Wen Deng, Yaqin Zhang, Weihua Cao, Xin Wei, Zixuan Gao, Linmei Yao, Shuojie Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Ziyu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xinxin LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yaqin ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Weihua CaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xin WeiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Zixuan GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Linmei YaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Shuojie WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the clinical characteristics of coronavirus disease 2019 (COVID-19) infection in patients with chronic hepatitis B (CHB) during interferon antiviral therapy and to explore the correlation between interferon use and COVID-19 infection and clinical indicators in these patients. A retrospective study was conducted on 477 Patient with CHB who visited the Second Hepatology Department of Ditan Hospital from December 2022 to February 2023. Patients were divided into an interferon group and a nucleoside analogue group based on whether they received interferon treatment. COVID-19 infection and fever duration were the primary indicators, while blood routine and liver function were the secondary indicators. Differences in COVID-19 infection rate, fever duration, and related laboratory tests between the two groups were compared. There were 184 patients in the interferon group and 293 patients in the nucleoside analogue group. The COVID-19 infection rate was 73.91 % (136/184) in the interferon group and 92.15 % (270/293) in the nucleoside analogue group, with a statistically significant difference (

Indexed as

Chronic hepatitis B (CHB)Clinical characteristicsCoronavirus Disease 2019 (COVID-19)Interferon

Identifiers

PMID41541060
PMCPMC12802339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.